is therefore considered addictive. In an experiment using rhesus monkeys to measure phendimetrazine's addictive potential, however, the test animals indicated no interest in it. This same study showed the drug having about 10% to 20% of dextroamphetamine's potency.

Drug interactions. Drinking milk can counteract phendimetrazine's anorectic quality. The drug can dangerously increase blood pressure by interacting with monoamine oxidase inhibitors (MAOIs, found in some antidepressants and other medicine). After highly publicized incidents of adverse effects associated with combination therapy of phentermine and fenfluramine, medical practitioners became especially alert to any problems associated with diet drugs. Someone taking phendimetrazine two times a day developed heart and lung difficulty that substantially improved when dosage was halted, and a case of temporary skin rash and kidney inflammation is reported from someone who was taking phendimetrazine and phentermine. The latter drug combination is also suspected of responsibility for temporary trouble with blood circulation in the brain (leading to a stroke in at least one instance). Whether these isolated cases can be extrapolated into general principle is questionable, but such reports raise questions worthy of further scientific investigation.

Cancer. Not enough scientific information to report.

Pregnancy. Impact on fetal development is unknown. The drug is not recommended for pregnant women.

Additional scientific information may be found in:

Hadler, A.J. "Sustained-Action Phendimetrazine in Obesity." Journal of Clinical Pharmacology 8 (1968): 113-17. Mazansky, H. "A Review of Obesity and Its Management in 263 Cases." South African

Medical Journal 49 (1975): 1955-62. Ressler, C., and S.H. Schneider. "Clinical Evaluation of Phendimetrazine Bitartrate."

Clinical Pharmacology and Therapeutics 2 (1961): 727-32. Rostagno, C., et al. "Dilated Cardiomyopathy Associated with Chronic Consumption of Phendimetrazine." American Heart Journal 131 (1996): 407-409. Runyan, J.W. "Observations on the Use of Phendimetrazine, a New Anorexigenic Agent, in Obese Diabetics." Current Therapeutic Research: Clinical and Experimental 4 (1962): 270-75.

Sash, S.E. "Anorectic Effects of OBEX LA (D-Phendimetrazine Bitartrate) in the Treatment of Obesity." Current Therapeutic Research: Clinical and Experimental 31 (1982): 181-84.

Continue reading here: Phenobarbital

Was this article helpful?

0 0